427 related articles for article (PubMed ID: 28087469)
21. The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis.
Boyle DL; Soma K; Hodge J; Kavanaugh A; Mandel D; Mease P; Shurmur R; Singhal AK; Wei N; Rosengren S; Kaplan I; Krishnaswami S; Luo Z; Bradley J; Firestein GS
Ann Rheum Dis; 2015 Jun; 74(6):1311-6. PubMed ID: 25398374
[TBL] [Abstract][Full Text] [Related]
22. Anti-inflammatory potential of PI3Kδ and JAK inhibitors in asthma patients.
Southworth T; Plumb J; Gupta V; Pearson J; Ramis I; Lehner MD; Miralpeix M; Singh D
Respir Res; 2016 Oct; 17(1):124. PubMed ID: 27716212
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of JAK-STAT and NF-κB signalling systems could be a novel therapeutic target against insulin resistance and type 2 diabetes.
Bako HY; Ibrahim MA; Isah MS; Ibrahim S
Life Sci; 2019 Dec; 239():117045. PubMed ID: 31730866
[TBL] [Abstract][Full Text] [Related]
24. JAK inhibition with tofacitinib suppresses arthritic joint structural damage through decreased RANKL production.
LaBranche TP; Jesson MI; Radi ZA; Storer CE; Guzova JA; Bonar SL; Thompson JM; Happa FA; Stewart ZS; Zhan Y; Bollinger CS; Bansal PN; Wellen JW; Wilkie DP; Bailey SA; Symanowicz PT; Hegen M; Head RD; Kishore N; Mbalaviele G; Meyer DM
Arthritis Rheum; 2012 Nov; 64(11):3531-42. PubMed ID: 22899318
[TBL] [Abstract][Full Text] [Related]
25. Effects of the Janus Kinase Inhibitor, Tofacitinib, on Testicular Leydig Cell Hyperplasia and Adenoma in Rats, and on Prolactin Signaling in Cultured Primary Rat Leydig Cells.
Chapin RE; Ball DJ; Radi ZA; Kumpf SW; Koza-Taylor PH; Potter DM; Mark Vogel W
Toxicol Sci; 2017 Jan; 155(1):148-156. PubMed ID: 27708194
[TBL] [Abstract][Full Text] [Related]
26. Tofacitinib Represses the Janus Kinase-Signal Transducer and Activators of Transcription Signalling Pathway in Keratinocytes.
Srivastava A; Ståhle M; Pivarcsi A; Sonkoly E
Acta Derm Venereol; 2018 Aug; 98(8):772-775. PubMed ID: 29738047
[TBL] [Abstract][Full Text] [Related]
27. JAK inhibition using tofacitinib for inflammatory bowel disease treatment: a hub for multiple inflammatory cytokines.
Danese S; Grisham M; Hodge J; Telliez JB
Am J Physiol Gastrointest Liver Physiol; 2016 Feb; 310(3):G155-62. PubMed ID: 26608188
[TBL] [Abstract][Full Text] [Related]
28. Tofacitinib attenuates arthritis manifestations and reduces the pathogenic CD4 T cells in adjuvant arthritis rats.
Gertel S; Mahagna H; Karmon G; Watad A; Amital H
Clin Immunol; 2017 Nov; 184():77-81. PubMed ID: 28461107
[TBL] [Abstract][Full Text] [Related]
29. Potential Involvement of the IL-6/JAK/STAT3 Pathway in the Pathogenesis of Intervertebral Disc Degeneration.
Suzuki S; Fujita N; Fujii T; Watanabe K; Yagi M; Tsuji T; Ishii K; Miyamoto T; Horiuchi K; Nakamura M; Matsumoto M
Spine (Phila Pa 1976); 2017 Jul; 42(14):E817-E824. PubMed ID: 27879577
[TBL] [Abstract][Full Text] [Related]
30. Inhibitory effect of JAK inhibitor on mechanical stress-induced protease expression by human articular chondrocytes.
Machida T; Nishida K; Nasu Y; Nakahara R; Ozawa M; Harada R; Horita M; Takeshita A; Kaneda D; Yoshida A; Ozaki T
Inflamm Res; 2017 Nov; 66(11):999-1009. PubMed ID: 28752178
[TBL] [Abstract][Full Text] [Related]
31. Renin-angiotensin system promotes colonic inflammation by inducing T
He L; Du J; Chen Y; Liu C; Zhou M; Adhikari S; Rubin DT; Pekow J; Li YC
Am J Physiol Gastrointest Liver Physiol; 2019 Jun; 316(6):G774-G784. PubMed ID: 30995068
[TBL] [Abstract][Full Text] [Related]
32. Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases.
Clark JD; Flanagan ME; Telliez JB
J Med Chem; 2014 Jun; 57(12):5023-38. PubMed ID: 24417533
[TBL] [Abstract][Full Text] [Related]
33. Tofacitinib Reprograms Human Monocytes of IBD Patients and Healthy Controls Toward a More Regulatory Phenotype.
Cordes F; Lenker E; Spille LJ; Weinhage T; Bettenworth D; Kessel C; Schmidt HH; Foell D; Varga G
Inflamm Bowel Dis; 2020 Feb; 26(3):391-406. PubMed ID: 31560043
[TBL] [Abstract][Full Text] [Related]
34. Tofacitinib in ulcerative colitis.
Archer TP; Moran GW; Ghosh S
Immunotherapy; 2016 May; 8(5):495-502. PubMed ID: 27140405
[TBL] [Abstract][Full Text] [Related]
35. Heme oxygenase-1 directly binds STAT3 to control the generation of pathogenic Th17 cells during neutrophilic airway inflammation.
Lin XL; Lv JJ; Lv J; Di CX; Zhang YJ; Zhou T; Liu JL; Xia ZW
Allergy; 2017 Dec; 72(12):1972-1987. PubMed ID: 28580587
[TBL] [Abstract][Full Text] [Related]
36. JAK2 inhibitors improve RA combined with pulmonary fibrosis in rats by downregulating SMAD3 phosphorylation.
Wei Y; Wang D; Wu J; Zhang J
Int J Rheum Dis; 2024 May; 27(5):e15164. PubMed ID: 38706209
[TBL] [Abstract][Full Text] [Related]
37. JAK/STAT pathway plays a critical role in the proinflammatory gene expression and apoptosis of RAW264.7 cells induced by trichothecenes as DON and T-2 toxin.
Wang X; Liu Q; Ihsan A; Huang L; Dai M; Hao H; Cheng G; Liu Z; Wang Y; Yuan Z
Toxicol Sci; 2012 Jun; 127(2):412-24. PubMed ID: 22454431
[TBL] [Abstract][Full Text] [Related]
38. Selective inhibition of JAK3 signaling is sufficient to reverse alopecia areata.
Dai Z; Chen J; Chang Y; Christiano AM
JCI Insight; 2021 Apr; 6(7):. PubMed ID: 33830087
[TBL] [Abstract][Full Text] [Related]
39. Brevilin A, a novel natural product, inhibits janus kinase activity and blocks STAT3 signaling in cancer cells.
Chen X; Du Y; Nan J; Zhang X; Qin X; Wang Y; Hou J; Wang Q; Yang J
PLoS One; 2013; 8(5):e63697. PubMed ID: 23704931
[TBL] [Abstract][Full Text] [Related]
40. Levetiracetam mitigates lipopolysaccharide-induced JAK2/STAT3 and TLR4/MAPK signaling pathways activation in a rat model of adjuvant- induced arthritis.
Abed El-Gaphar OAM; Abo-Youssef AM; Halal GK
Eur J Pharmacol; 2018 May; 826():85-95. PubMed ID: 29501867
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
